IntroductIon
While recent trends in stabilizing incidence and decreasing mortality rates are encouraging, prostate cancer (CaP) remains a major health burden for American men. 1 Similar to other cancers, prostate cancer develops through a multi-step process of genetic changes, each providing some type of growth advantage for cells, leading to their progressive conversion into aggressive cancer cells. Intensive investigations on CaP-specific genetic alterations are beginning to define common genetic changes in CaP. [2] [3] [4] Chromosomal rearrangements/translocations leading to activation of ETS transcription factors (ERG, ETV1 and ETV4) or methylation mediated silencing of protective genes such as GSTP1 appear to be most common potentially causal gene alterations in CaP. 2, 5 Expression alterations of the GSTP 1,6 DD 3,7 AMACR, 8 and proto-oncogene, ERG, 9 represent the most frequent CaP associated gene expression changes.
LTF, a non-heme iron binding glycoprotein, belongs to the transferrin gene family and arose from an ancient intragenic duplication. 10 LTF was first discovered in milk and was also found in a variety of secretions derived from glandular epithelium cells, such as prostate and salivary glands as well as in many biological secretions including tears and semen. LTF plays an immunomodulatory role and participates in inflammatory response. A number of reports suggested that LTF has an antitumorigenic role 11 utilizing a variety of mechanisms including regulation of NK (natural Killer) cell activity, 12 modulation of expression of G 1 proteins, 13 and enhancement of apoptosis. 14 LTF has anti-tumor function and could inhibit development of tumors in animal models. 10, 15 Bovine lactotransferrin (bLTF) has been found to significantly inhibit colon, esophagus, lung, bladder and liver cancers in rats. [16] [17] [18] [19] [20] Moreover, bLTF was shown to be chemopreventive in liver carcinogenesis induced by diethyl nitrosamine (DEN) alone or by DEN plus 2-amino-3, 8-dimethylimidazo [4,5- f ]quinoxaline (MeIQx), or in MeIQx-induced colon carcinogenesis in rat animal models. 21 However, the role of LTF in human prostate cancer remains to be defined. In this study, we evaluated the expression of LTF gene in CaP specimens and assessed the prognostic value of decreased or lost LTF expression in CaP progression. Furthermore, we investigated the mechanism of LTF downregulation and the cell growth inhibitory effects of LTF in prostate cancer cell model systems.
MAtErIALs And MEtHods
GeneChip ® analyses. Total RNA was isolated from LCM derived tumor and benign epithelial cells according to protocol number WRAMC WU# 04-2871-98k. The RNA was quantitated, amplified, biotinylated, and hybridized to high-density oligonucleotide human genome array HG U133A (Affymetrix, Santa Clara, CA). 9 The gene expression data from paired benign and malignant prostate epithelial cells from 20 patients (40 GeneChips ® ) were subjected to multidimensional scaling (MDS) analysis as described previously. 9 Validation of LTF expression by QRT-PCR. Total RNA isolated from the LCM derived tumor and benign epithelial cells, was converted to cDNA (Sensiscript, Qiagen, Valencia, CA). Quantitative gene expression analysis was performed by TaqMan-based QRT-PCR as described. 9 LTF copy number was determined in tumor and benign samples (n = 100) and normalized to GAPDH copy numbers. 22 Statistical analyses were performed using the SAS software package (version 9.0, SAS Institute Inc., Cary, NC). PSA recurrence free survival was correlated with LTF expression ratio. 23 Northern blot analysis. Twenty micrograms of total RNA from LNCaP and LAPC4 cells and RNA Millennium™ Markers (Ambion Inc., TX, USA) were electrophoresed in denaturing formaldehyde 1% agarose gels. Following overnight capillary transfer to Protran Pure Nitrocellulose Transfer and Immobilization Membranes (Schleicher & Schuell Keene, N.H., USA). Blots were probed with LTF cDNA of 2.9 Kb in size (OriGene Technologies, Inc., Rockville, MD USA), GAPDH-Mouse DECAprobe template and Millennium Marker™ Probe Template (Ambion Inc., TX, USA), which were radioactively labeled with a-32p-dCTP (GE Healthcare, Buckinghamshire, UK) using a random-primed DNA labeling kit named, Amersham Rediprime™ II Random Prime Labeling Systems (GE Healthcare, Buckinghamshire, UK). Hybridization was carried out for approximately 18 h in NorthernMax Prehybridization/ Hybridization buffer (Ambion Inc., Tex., and USA). The membrane was washed twice with 1x SSC and 0.1% SDS for 15 min each and then washed twice with 0.25 x SSC and 0.1% SDS for 15 min each and autoradiographed. Sizes of the target genes were determined from RNA Millennium™ Markers on the autoradiograph.
Analysis of LTF protein expression by immunohistochemisrty (IHC). All tissues were fixed in 10% neutral buffered formalin and were paraffin embedded. Prostate tissue specimens were selected with the criteria of having sufficient tissue within the paraffin block to perform the immunohistochemistry (IHC). Tissue sections (100 mm) of the radical prostatectomy derived whole-mount prostate specimens from 30 CaP patients were stained with H&E and anti-LTF by IHC. 24 Determination of LTF protein concentration in CaP patient Serum. Serum LTF protein concentration of biopsy-verified CaP patients who underwent radical prostatectomy at Walter Reed Army Medical Center (WRAMC) was compared to CaP-free control group with normal digital rectal examination (DRE) and a low serum PSA (<2.5 ng/ml). Serum LTF levels were measured in a cohort of 34 CaP patients and 35 healthy male controls using Bioxytech Lacto-f-EIA (OxisResearch, Portland, OR) and a Multiskan Ascent ELISA plate reader according to the manufacturer's recommendation.
Activation of LTF expression in LNCaP cells by 5-azadeoxycytidine treatment. LNCaP and LAPC4 cells were treated with 5 mM of 5-azadeoxycytidine DNA methyl transferase inhibitor (Sigma-Aldrich Co., St. Louis, MO) for 14 days at concentration of 5 mM with the change of cell culture media every two days (concentration was optimized prior to the actual experiment to avoid toxicity). Quantitative methylation analysis of genomic DNA from treated and untreated LNCaP cells were performed by SequEnom ® (San Diego, CA) using EpiTYPER, a bisulfite-treatment-based MALDI-TOF MS method for detection and quantitation of methylation. 25 To amplify the bisulfite modified +200 to +600 CpG-rich region of the LTF gene, a primer pair was designed as follows: forward primer, 5'-GGGGTAAAGTTTTGAATAAAGGGG-3' and reverse primer 5'-TAAAAAACCCAACTATTCCTCC-3'. The GSTP1 gene -300; +100 region was amplified by using the following primer set: forward 5' TGGGAAAGAGGGAAAGGTTTTTT-3' and reverse 5'-CCCATACTAAAAACTCTAAACCCCATC-3'. For gene expression analysis total RNA was extracted from untreated and 5-azadeoxycytidine treated LNCaP and LAPC4 cells using RNeasy Mini kit (QIAGEN ® , Valencia, CA). For gene expression analysis total RNA was extracted from untreated and 5-azadeoxycytidine treated LNCaP and LAPC4 cells using RNeasy Mini kit (QIAGEN ® , Valencia, CA). The RNA was transferred on nitrocellulose membrane to asses the expression of LTF by Northern Blot analysis in both LNCaP and LAPC4 cells as described above. GAPDH expression was assessed as the quality control of RNA samples.
Effects of LTF on LNCaP cell proliferation and cell cycle. LNCaP cells (5 x 10 4 cells/well, passage 28) in RPMI medium were plated into 12-well plates and allowed to grow in a 5% CO 2 incubator at 37˚C for 24 hours. LTF dose response was assayed by supplementing the media with various concentrations of LTF protein (Sigma-Aldrich, St. Louis, MO) from a 1000 mM stock solution to final concentrations of 0, 10, 30 and 50 mM. Cell growth was determined at 24, 48, 72 and 96 hours. The experiment was performed in triplicate (n = 3) and repeated twice. Cell morphology was monitored and photographed using an inverse microscope (DMIRE2, Leica Microsystems, Bannockburn, IL). Statistical analysis was performed with SPSS version 12 software package. p < 0.05 values were considered to be statistically significant. For cell cycle analysis Propidium Iodide (PI) staining and FACS analysis was performed. The fluorescent dye Propidium Iodide preferentially binds to double-stranded nucleic acids and allows fluorescent intensity to be used as an indicator of the cellular DNA content. LNCaP cells were grown to ~70% confluence in 25-cm 2 flasks and were treated with 10 mM of human lactoferrin for 24 h and 48 h at 37˚C. Following treatments, the adherent cells were trypsinized and washed twice 1x PBS and then fixed with 70% cold ethanol at -20˚C for 30 min. Cells were washed twice with cold PBS following ethanol fixation. Cells were resuspended in PBS containing 10 mg/ml RNase (Boehringer Mannheim, Indianapolis, IN) and incubated at 37˚C for 30 min to remove double stranded RNA. Subsequently, cells were stained with PI (Boehringer Mannheim, Indianapolis, IN) at a concentration of 50 mg/ml and stored at 4˚C in the dark until flow cytometry was performed. PI stained LNCaP cells were analyzed using an EPICS ELITE ESP (Beckman Coulter, Miami, FL) flow cytometer. Cell cycle analysis of DNA histogram is performed with ModFit LT software (Verity Software House, Topsham, ME). Experiments were carried out in triplicates.
rEsuLts
LTF mRNA and protein levels are downregulated in prostate cancer. Evaluations of prostate epithelial cell (PEC) transcriptome using laser capture microdissection (LCM) derived benign and tumor epithelial cells and Affymetrix GeneChipÒ revealed LTF (downregulated in tumor cells) and AMACR (upregulated in tumor cells) as the most significant (p < 10-6) malignant cell-specific differential expression (Fig. 1A) . CaP associated LTF expression alteration was validated at protein level. Significant downregulation of LTF protein was noted in all 30 whole-mount paraffin embedded formalin fixed tissue specimens of CaP patients analyzed by IHC (Fig. 1B) . In these experiments an average of 20% focal tumor stains for LTF was detectable. Patients with organ-confined CaP (n = 34) had significantly lower levels of serum LTF (p < 0.0001) compared to control group with normal DRE and low PSA (n = 35) as determined by ELISA (Fig. 1C) .
Quantitative assessment of LTF downregulation revealed an association with reduced PSA recurrence-free survival. LTF mRNA copy numbers normalized to GAPDH copy numbers were determined in 200 RNA specimens from laser micro-dissected matched tumor (T) and benign (B) prostate epithelial cells of 100 CaP patients. Decreased LTF expression was noted in tumor cells of 74.0% CaP patients, while 21% of CaP patients had increased LTF expression ( Fig. 2A) . As a quality control for the LCM-RNA specimens, a subset of RNAs from 20 benign and 20 tumor samples were analyzed for AMACR and GSTP1. As expected, AMACR overexpression (95%) and decreased GSTP1 expression (100%) was observed in virtually all tumor specimens ( Supplementary Fig. 1 ). Low LTF "Tumor (T) / Benign (B)" expression (copy number) showed a significant correlation with shorter PSAR-free survival by Kaplan-Meier unadjusted analysis (p value ≤0.0322; Fig. 2B ). Using chi-square analysis, a significant association Table 1 ). These data suggest that low "T/B" LTF expression is a potential biomarker of poor prognosis of CaP. These data suggest that low "T/B" LTF expression is a potential biomarker of poor prognosis of CaP.
Mechanism of LTF downregulation in LNCaP cells.
To elucidate the possible mechanism of LTF gene silencing we analyzed the LTF promoter upstream and downstream sequences for CpG islands. The analysis revealed a CpG island downstream to the transcription initiation site. To assess whether or not DNA methylation played a role in LTF gene silencing LNCaP and LAPC4 cells harboring mutant or wild type AR respectively, were incubated in the absence or presence of 5 mM 5-azadeoxycytidine(decitabine) DNA methyl transferase inhibitor for 15 days. Genomic DNA was isolated from the cells and quantitative methylation analyses was carried out by EpiTYPER MALDI-TOF MS, a bisulfite-treatment-based method for the detection and quantitation of DNA methylation. 25 In cells without decitabine treatment the CpG-rich region spanning from exon 1 to the downstream intronic sequences (+200 to +600 relative to the transcription initiation site of LTF promoter), an average of 80% methylation was found in mutant AR expressing LNCaP cells (Fig. 3A) . In contrast, an average of 35% methylation was observed in the same region in wild type AR expressing LAPC4 cells. (Fig. 3C) . Proportional demethylation was observed in response to 5-aza-deoxycytidine treatments at CpG sites throughout the assessed region in both cell lines. Consistent decreases in GSTP1 methylation in response to 5-aza-deoxycytidine treatments confirmed that decitabine concentration was in the subtoxic concentration range facilitating the demethylation of CpG islands (Fig. 3, B and D) . Assessment of LTF mRNA levels by Northern blot analyses indicated robust increases in wild type AR harboring LAPC4 cells and in a lesser extent in LNCaP in response to decitabine (Fig. 3E ). These observations were consistent with the finding of high levels of DNA methylation in genome of mutant AR harboring LNCaP cells (Fig. 3A) . 26 LTF protein inhibits the growth of prostate cancer cells. Numerous studies have demonstrated the negative effect of LTF protein supplementation on the growth of various cancer cells. Therefore, we evaluated the effect of LTF on prostate cancer cell For this analysis, LTF expression data were dichotomized using the median split of log-transformed LTF copy number ratio (T/B) data, resulting in the following strata: ≤ -1.861 ("Low") versus > -1.861 ("High"). C, PSA recurrence (PSAR) after radical prostatectomy (RP) in CaP patients is significantly higher among men with low T/B LTF expression in RP specimens (N = 107). PSAR was defined as a single, post-operative PSA value of 0.2 ng/ml at ≥ 2 months post-RP. LTF expression data were dichotomized using the median split of log-transformed LTF copy number ratio (T/B) data, resulting in the following strata: ≤ -1.861 ("Low") versus > -1.861 ("High"). Chi-square analysis revealed that 88% of PSAR events in the study sample were observed in men with low LTF expression (Chi-square = 5.32, df = 1, p = 0.02). 4A and B) . We noted that cell number was not reduced within the first 24 hours of LTF treatment (data not shown). After 48 hours the number of LNCaP cells was significantly reduced in response to 10 mM LTF treatment (Fig. 4A) . While 10 mM LTF concentration was cytostatic (p < 0.01 for each pair), ≥30 mM LTF appeared to be cytotoxic (Fig. 4B) . Both cytostatic and cytotoxic effects of LTF on LNCaP cells were evident by the observed changes in cell morphology. LTF induces apoptosis and growth arrest at the G 1 phase of the cell cycle. To assess the effects of LTF treatment on cell cycle regulation LNCaP cells were treated with 10 mM of human lactoferrin for 24 and 48 hours and were compared to untreated cells by FACS analysis. Robust apoptosis (G 0 ) and growth arrest at the G 1 phase was observed in the 24 and 48 hours groups in response to 10 mM LTF treatment (Fig. 5) . Furthermore, reduction in S-phase of the cell cycle was apparent in all treatment groups. Longer treatment or higher concentrations of LTF appeared to be cytotoxic (data not shown).
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dIscussIon
Detection of the frequently downregulated LTF in CaP may provide a valuable tool for monitoring disease progression. Association of LTF downregulation with decreased PSA recurrence-free survival of CaP patients suggests that LTF may be suitable for disease prognosis. Consistent with the LTF mRNA expression data, LTF protein downregulation was observed both in tumor tissue and in serum (p < 0.0001). In quantitative gene expression evaluation of LCM-selected cells, downregulation of LTF mRNA expression was observed in 74% of the samples. IHC results of whole-mount prostates from 30 patients suggested absence of LTF expression in approximately 80% of tumors. Interestingly, specimens with increased LTF expression showed better prognosis (longer PSA recurrence free survival) of CaP that may reflect the preventive function of LTF in these patient group. The cell growth inhibitory effect of LTF protein on CaP cells is intriguing and indicates protective functions for LTF in CaP. Although, further studies will be necessary to assess possible mechanisms 27 leading to cell growth inhibitory properties of LTF in prostate cells. It has been reported before that LTF expression might be silenced by promoter hypermethylation in CaP. 10 Furthermore, we previously shown that CaP cells harboring wild type or mutant alleles of AR are different in their genomic DNA methylation levels and in their response to inhibition of DNA methyl transferases. 26 Therefore, we addressed the question of whether or not silencing of LTF promoter is affected by the allelic status of AR in CaP cell culture models. Indeed, in mutant AR harboring LNCaP cells the LTF promoter downstream CpG island was heavily methylated, and LTF expression was undetectable. In contrast, analysis of wild type AR expressing LAPC4 cells indicated modest methylation within the promoter downstream CpG island and detectable levels of LTF expression. Inhibition of DNA methyl transferases by decitabine resulted in robust activation of LTF expression in LAPC4 and in to a lesser extent activation of LTF in LNCaP cells. These data together indicate that methylation silencing of LTF may mirror the functional status of androgen receptor. Although, methylation silencing of LTF gene closely resembles the silencing of the protective GSTP1 gene that is an early event in CaP, 5 LTF methylation may be intimately linked to the chromatin changes associated with AR functions in prostate cancer.
Early recurrence of CaP after RP is detectable by a rise in serum PSA level 23 and PSA recurrence develops in a significant number of patients who undergo RP, which is commonly considered as an early indication of progressive disease. Prognostic molecular markers of CaP progression predicting PSA recurrence and disease-specific survival have been extensively evaluated in CaP tissues. 28 Expression features of genes such as p53, 17 BCL2, 28 EZH2, 29 AMACR8 and ERG19 appear to be associated with PSA recurrence after RP. Significant association of LTF downregulation with PSA recurrence also suggests that LTF may play protective roles in the prostate epithelium.
Use of natural compounds such as lactoferrin in chemoprevention and chemotherapy may become a useful strategy in suppressing and inhibiting tumor growth and carcinogenesis. Interestingly, growth inhibition of LNCaP cells by LTF protein suggests potential antitumorigenic activity of LTF in CaP. We evaluated changes in the cell cycle of prostate cancer cells in response to lactoferrin treatment to assess underlying mechanisms of the lactoferrin-mediated antitumorigenic activity. Robust apoptotic response (G 0 ), growth arrest at G 1 and reduced S phase was observed in response to lactoferrin treatment suggesting a role for specific cell cycle regulatory mechanisms in LTF-mediated cell growth inhibition. Similar observations were reported in Head and Neck cancer cell, 30 hepatocyte 31 and breast cancer 32 cell models. Numerous reports suggested that LTF has antitumorigenic activity in animal models in various cancer types. These studies have shown that LTF can inhibit development of tumors in experimental models. 15, 33 Our data warrants similar investigations for LTF in prostate cancer.
Taken together, this study has established LTF as a frequently downregulated gene in CaP. As the magnitude of LTF mRNA downregulation in prostate tumor cells is significantly associated with PSA recurrence after RP, quantitative features of LTF expression have prognostic utility in disease progression. Reduced levels of LTF protein in tumor specimens and blood samples hold the promise for providing alternative strategies for assessing the prognostic value of LTF in the serum of CaP patients. Finally, the observed cell growth inhibitory effects of this natural milk product, warrants future experiments evaluating the anti-tumorigenic effects of LTF in prostate cancer in the context of chemoprevention. 
